Page last updated: 2024-10-15

tirapazamine

Description

Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135413511
CHEMBL ID50882
CHEBI ID78887
SCHEMBL ID872285
SCHEMBL ID4048
SCHEMBL ID4049
MeSH IDM0142901

Synonyms (61)

Synonym
27314-97-2
nsc-130181
3-aminobenzo[e][1,2,4]triazine 1,4-dioxide
tirazone
sr-259075
tirapazamine
sr-4233
win-59075
win 59075
1,2,4-benzotriazin-3-amine, 1,4-dioxide
sr 4233
nsc 130181
3-amino-1,2,4-benzotriazine 1,4-dioxide
brn 0179322
1,2,4-benzotriazine, 3-amino-, 1,4-dioxide
tirapazamine [usan:inn]
tirapazamine (usan/inn)
D06167
CHEMBL50882
sr259075
chebi:78887 ,
4-hydroxy-1-oxido-1,2,4-benzotriazin-1-ium-3-imine
FT-0661586
AKOS006271584
unii-1ud32yr59g
4-26-00-01120 (beilstein handbook reference)
1ud32yr59g ,
BCP0726000167
1,2,4-benzotriazin-3-amine 1,4-dioxide
1,2,4-benzotriazin-3-amine,1,4-dioxide
tirapazamine [usan]
tirapazamine [mi]
tirapazamine [mart.]
tirapazamine [who-dd]
tirapazamine [inn]
SCHEMBL872285
DB04858
HY-13767
SCHEMBL4048
SCHEMBL4049
ORYDPOVDJJZGHQ-UHFFFAOYSA-N
AC-31305
4-hydroxy-3-imino-3,4-dihydro-1,2,4-benzotriazin-1-ium-1-olate
AS-64112
tirapazamine, >=98% (hplc)
J-016728
sr259075;sr4233;win59075
BCP03663
Q3529346
3-aminobenzo[e][1,2,4]triazine1,4-dioxide
T3823
EX-A2967
bdbm50226806
mfcd00132954
NCGC00390788-04
AMY38675
sr4233
win59075
T72208
AKOS037645846
1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine

Research Excerpts

Overview

Tirapazamine (TPZ) is an anticancer drug with highly selective cytotoxicity toward hypoxic cells. It may exert synergistic tumor-killing activity with transcatheter arterial embolization (TAE) for liver cancer.

ExcerptReference
"Tirapazamine (TPZ) is a promising hypoxia-selective cytotoxic agent that may exert synergistic tumor-killing activity with transcatheter arterial embolization (TAE) for liver cancer. "( Tirapazamine-loaded CalliSpheres microspheres enhance synergy between tirapazamine and embolization against liver cancer in an animal model.
Guo, X; Hong, W; Li, L; Li, Q; Liang, B; Liu, Y; Zhang, L; Zhang, X; Zhao, D; Zheng, C, 2022
)
"Tirapazamine (TPZ) is a HAP which has undergone extensive clinical evaluation in this context and stimulated development of optimized analogues."( Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
Abbattista, MR; Anderson, RF; Denny, WA; Guise, CP; Hay, MP; Hicks, KO; Lee, SJ; Li, D; Patterson, AV; Smaill, JB; Taghipouran, R; Tsai, A; Wilson, WR, 2020
)
"Tirapazamine is a hypoxia-activated prodrug which was shown to exhibit up to 300 times greater cytotoxicity under anoxic in comparison with aerobic conditions. "( Tirapazamine has no Effect on Hepatotoxicity of Cisplatin and 5-fluorouracil but Interacts with Doxorubicin Leading to Side Changes in Redox Equilibrium.
Burdan, F; Dudka, J; Grzycka-Kowalczyk, L; Hejna, M; Jodlowska-Jedrych, B; Korga, A; Korobowicz-Markiewicz, A; Kowalczyk, M; Mandziuk, S; Matysiak, W; Pasnik, I; Poleszak, E, 2016
)
"Tirapazamine (TPZ) is an anticancer drug with highly selective cytotoxicity toward hypoxic cells. "( Cytotoxicity of Tirapazamine (3-Amino-1,2,4-benzotriazine-1,4-dioxide)-Induced DNA Damage in Chicken DT40 Cells.
Masunaga, SI; Moriwaki, T; Nagasawa, H; Okamoto, S; Sasanuma, H; Takeda, S; Tano, K, 2017
)
"Tirapazamine (TPZ) is a newer class of cytotoxic drugs with selective toxicity towards hypoxic mammalian cells."( Tirapazamine: a novel agent targeting hypoxic tumor cells.
Reddy, SB; Williamson, SK, 2009
)
"Tirapazamine (TPZ) is a synthetic hypoxia-activated prodrug, which preferentially forms cytotoxic and DNA-damaging free radicals under hypoxia, thus selectively eradicate hypoxic cells."( Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.
Chan, AT; Cheng, SH; Hong, B; Hui, EP; Lui, VW; Ng, MH; Sung, FL; Tsang, CM; Tsao, SW, 2011
)
"Tirapazamine is a bioreductively activated DNA-damaging agent that selectively kills the hypoxic cells found in solid tumors. "( Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Ganley, B; Gates, KS; Kotandeniya, D, 2002
)
"Tirapazamine (TPZ) is a bioreductive agent that forms a toxic-free radical in hypoxia."( Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
Anderson, CP; Keshelava, N; Reynolds, CP; Yang, B, 2003
)
"Tirapazamine is a bioreductively activated DNA-damaging agent that selectively kills the hypoxic cells found in solid tumors. "( DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Birincioglu, M; Chowdhury, G; Dizdaroglu, M; Gates, KS; Jaruga, P; Rodriguez, H, 2003
)
"Tirapazamine is a cytotoxin that selectively targets hypoxic cells and has supra-additive toxicity with platinums and taxanes in preclinical studies."( Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Doroshow, JH; Frankel, P; Galvin, I; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Mack, PC; Martel, CL, 2003
)
"Tirapazamine (TPZ) is a bioreductive agent that forms a toxic free radical in hypoxia."( Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.
Reynolds, CP; Yang, B, 2005
)
"Tirapazamine (TPZ) is an anticancer drug that targets topoisomerase II. "( Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae.
Hellauer, K; Lesage, G; Sdicu, AM; Turcotte, B, 2005
)
"Tirapazamine is a cytotoxin that selectively targets hypoxic cells."( Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
Crowley, JJ; Gandara, DR; Lara, PN; Lau, DH; McCoy, J; Mills, GM; Tucker, RW; Williamson, SK, 2005
)
"Tirapazamine is a hypoxic cytotoxin currently undergoing Phase II/III clinical evaluation in combination with radiation and chemotherapeutics for the treatment of non-hematological cancers. "( Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.
Baker, JH; Huxham, LA; Kyle, AH; McNicol, KL; Minchinton, AI, 2006
)
"Tirapazamine (TPZ) is an anticancer drug that is selectively activated by the low oxygen environment in solid tumors. "( [Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model].
Adam, M; Busch, R; Erhardt, W; Künzel, G; Molls, M; Nieder, C; Ottenjann, S, 2006
)
"Tirapazamine is a chemotherapeutic agent that acts via a free radical mechanism."( Assessment of DNA damage at the dimer level: measurement of the formamide lesion.
Bailey, DT; Box, HC; Budzinski, EE; Dawidzik, JB; DeFedericis, HC; Evans, MS; Freund, HG; Greene, KF; Iijima, H; Patrzyc, HB, 2007
)
"Tirapazamine (SR 4233) is a benzotriazine di-N-oxide which acts as a hypoxic cytotoxic agent and as a radiation enhancer when given shortly before or after radiation. "( Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation.
Coleman, CN; Doherty, N; Hancock, SL; Kaye, S; Mariscal, C; Marquez, C; Rampling, R; Roemeling, RV; Senan, S; Shulman, L, 1994
)
"Tirapazamine is a bioreductive agent which, by"( Hypoxic sensitizer and cytotoxin for head and neck cancer.
Giuliano, J; Lee, DJ; Moini, M; Westra, WH, 1996
)
"Tirapazamine (TPZ) is a hypoxia-selective bioreductive drug currently in Phases II and III clinical trials with both radiotherapy and chemotherapy. "( Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
Brown, JM; Dorie, MJ; Menke, DR; Siim, BG, 1997
)
"Tirapazamine (SR 4233) is a benzotriazine compound exhibiting substantial differential toxicity for hypoxic cells. "( Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer.
Aghajanian, C; Brown, C; Curtin, J; Fleischauer, A; O'flaherty, C; Roemeling, R; Spriggs, DR, 1997
)
"Tirapazamine and cisplatin is an interesting drug combination in the treatment of cervical cancer. "( Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer.
Aghajanian, C; Brown, C; Curtin, J; Fleischauer, A; O'flaherty, C; Roemeling, R; Spriggs, DR, 1997
)
"Tirapazamine is a bioreductive compound synergistic with cisplatin in preclinical testing. "( Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
Grant, SC; Heelan, RT; Kindler, H; Kris, MG; Miller, VA; Ng, KK; Pizzo, B; von Roemeling, R, 1997
)
"Tirapazamine is a novel bioreductive agent with selective cytotoxicity to hypoxic tumour cells, irrespective of their p53 status or apoptotic response, and acts synergistically with cisplatin."( Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
Brown, JM, 1998
)
"Tirapazamine is a novel bioreductive agent with selective cytotoxicity against hypoxic tumour cells. "( Tirapazamine-cisplatin: the synergy.
Gatzemeier, U; Miller, V; Rey, A; Rodriguez, G; Treat, J; Viallet, J; von Roemeling, R, 1998
)
"Tirapazamine is a hypoxic cell cytotoxin in phase II/III trials. "( Hypoxic cell cytotoxin tirapazamine induces acute changes in tumor energy metabolism and pH: a 31P magnetic resonance spectroscopy study.
Aboagye, EO; Bhujwalla, ZM; Dillehay, LE; Lee, DJ, 1998
)
"Tirapazamine is a bioreductive drug with specific cytotoxicity in hypoxic conditions."( Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
Stevens, G; Zhang, M, 1998
)
"Tirapazamine (TPZ) is a new anticancer drug that is activated specifically at the low oxygen level typically found in solid tumours. "( Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin.
Brown, JM; Evans, JW; Hocking, DJ; Kovacs, MS; Siim, BG; Wouters, BG, 1999
)
"Tirapazamine (TPZ) is a bioreductive drug that exhibits greatly enhanced cytotoxicity in hypoxic tumor cells, which are frequently radiation-resistant and chemoresistant. "( Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi, Y; Waxman, DJ, 2000
)
"Tirapazamine (SR 4233) is a bioreductive antitumour drug in Phase III clinical trial which is activated in hypoxic tumour regions to generate a cytotoxic species. "( Electron paramagnetic resonance spectrometry evidence for bioreduction of tirapazamine to oxidising free radicals under anaerobic conditions.
Patterson, LH; Taiwo, FA, 2000
)
"Tirapazamine (TPZ) is a bioreductive drug that exhibits a high degree of selective toxicity toward hypoxic cells, and at doses that are used clinically, little or no cell killing is observed in aerobic cells. "( Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine.
Birrell, GW; Brown, JM; Chiu, RK; Delahoussaye, YM; Dorie, MJ; Evans, JW; MacDermed, D; Wang, J; Wouters, BG, 2001
)
"Tirapazamine (1) is a promising antitumor agent that selectively causes DNA damage in hypoxic tumor cells, following one-electron bioreductive activation. "( 3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Barnes, CL; Chowdhury, G; Fuchs, T; Gates, KS, 2001
)
"Tirapazamine (TPZ) is a hypoxia-selective cytotoxin that is currently being examined in Phase II and III clinical trials in combination with radiotherapy and cisplatin-based chemotherapy. "( Inhibition of DNA replication by tirapazamine.
Brown, JM; Iliakis, G; Peters, KB; Wang, H, 2001
)

Effects

Tirapazamine has been shown to enhance the cytotoxic effects of ionizing radiation in hypoxic cells. It has been clinically tested in combination with cisplatin at escalating doses in a phase I trial and at therapeutic doses in three separate phase II trials.

ExcerptReference
"Tirapazamine (TP) has been shown to enhance the cytotoxic effects of ionizing radiation in hypoxic cells, thus making it a candidate for a radiosensitizer. "( Electronic structure and reactivity of tirapazamine as a radiosensitizer.
Limão-Vieira, P; Maihom, T; Probst, M; Romero, J, 2021
)
"Tirapazamine has been clinically tested in combination with cisplatin at escalating doses in a phase I trial and at therapeutic doses in three separate phase II trials in patients with advanced non-small-cell lung cancer (NSCLC) in 11 study centres."( Tirapazamine-cisplatin: the synergy.
Gatzemeier, U; Miller, V; Rey, A; Rodriguez, G; Treat, J; Viallet, J; von Roemeling, R, 1998
)

Actions

Tirapazamine did not increase cure rate beyond that of MSC + CPT-11 combination and was instead found to decrease cures. No evidence of an increased DNA damage or a significant reduction in avascular hypoxic tumor regions.

ExcerptReference
"Tirapazamine did not increase cure rate beyond that of MSC + CPT-11 combination and was instead found to decrease cures with no evidence of an increased DNA damage or a significant reduction in avascular hypoxic tumor regions."( Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Bhattacharya, A; Cao, S; Chintala, S; Durrani, FA; Rustum, YM; Slocum, HK; Tóth, K, 2008
)
"Tirapazamine did not cause myelosuppression, and no toxic deaths were reported in these trials."( Tirapazamine-cisplatin: the synergy.
Gatzemeier, U; Miller, V; Rey, A; Rodriguez, G; Treat, J; Viallet, J; von Roemeling, R, 1998
)
"Tirapazamine did not increase the toxicity of paclitaxel, paraplatin, or their combinations as judged by its minimal impact on body weight and the fact that no toxic deaths were observed with tirapazamine-containing regimens."( Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.
Dexter, D; Hilsenbeck, S; Juniewicz, P; Mangold, G; Marty, J; Rake, J; Von Hoff, D; Weitman, S, 1999
)

Treatment

Tirapazamine treatment significantly reduced the presentation of metastases following radiotherapy (P = 0.003 versus saline controls) whereas RB6145 had no effect. Pretreatment with tirapazamines could enhance the sensitivity of tumor cells, including Q cells, to radiation more markedly than mitomycin C pretreatment.

ExcerptReference
"Tirapazamine treatment significantly reduced the presentation of metastases following radiotherapy (P = 0.003 versus saline controls) whereas RB6145 had no effect."( Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
Fitzmaurice, RJ; Lunt, SJ; Stratford, IJ; Telfer, BA; Williams, KJ, 2005
)
"Pretreatment with tirapazamine, a bioreductive agent, could enhance the sensitivity of tumor cells, including Q cells, to radiation more markedly than mitomycin C pretreatment as judged from an in vivo assay immediately after irradiation."( Effects of bioreductive agents, tirapazamine and mitomycin C, on quiescent cell populations in solid tumors, evaluated by micronucleus assay.
Akaboshi, M; Hori, H; Kinashi, Y; Masunaga, S; Ono, K; Shibata, T; Suzuki, M; Takagaki, M, 1997
)

Toxicity

Tirapazamine (SR 4233) is a bioreductive drug selectively toxic towards hypoxic cells. It is presently in phase II clinical trials.

ExcerptReference
" All agents chosen for these experiments represented classes of compounds known to be more toxic towards hypoxic cells than they are to aerobic cells."( The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay.
Stephens, MA; Stratford, IJ, 1989
)
" It has been found to be 15 to 200 times more toxic to hypoxic rodent and human cell lines than their normoxic counterparts."( In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent.
Baker, MA; Brown, JM; Costa, AK; Trudell, JR, 1989
)
"The metabolism of SR 4233 (3-amino-1,2,4-bentotriazine-1,4-dioxide), recently reported as highly toxic to hypoxic cells in vitro, was studied by using suspensions of Chinese hamster ovary cells."( Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity.
Baker, MA; Brown, JM; Hirst, VK; Zeman, EM, 1988
)
" The toxic product(s) is unknown, but could be the 1-electron reduction product, the radical anion, because the mono N-oxide (the 2-electron reduction product) did not display cytotoxicity or selective killing under hypoxic conditions."( SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
Brown, JM; Hirst, VK; Lee, WW; Lemmon, MJ; Zeman, EM, 1986
)
"One potential mechanism of aerobic cytotoxicity is redox cycling of SR 4233 with molecular oxygen resulting in several potentially toxic oxidative species that overburden the intrinsic intracellular detoxification systems such as superoxide dismutase, catalase, and glutathione peroxidase."( Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron.
Biaglow, JE; Coleman, CN; Cook, JA; Gonzalez, FJ; Herscher, LL; Krishna, MC; Mitchell, JB; Tuttle, SW, 1994
)
"SR-4233 is activated to a toxic species by bioreductive metabolism."( Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air.
Biaglow, JE; Coleman, CN; Hazard, L; Koch, CJ; Mitchell, JB; Tuttle, SW, 1994
)
" The oxygen dependence of the toxic response has not previously been characterized."( Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.
Koch, CJ, 1993
)
"SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide) is the lead compound of the benzotriazene-di-N oxides which are selectively toxic to tumour cells under hypoxic conditions."( Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions.
O'Brien, PJ; Silva, JM, 1993
)
"Tirapazamine (SR 4233), a bioreductive drug selectively toxic towards hypoxic cells, is presently in phase II clinical trials."( Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
Brown, JM; Siim, BG; van Zijl, PL, 1996
)
"133 mmol/kg) significantly enhanced hypoxic cell killing in HT29 tumor xenografts without causing oxic cell killing, and the combination at its maximum tolerated dose was less toxic to hypoxic cells in the retina than was TPZ alone at its maximum tolerated dose."( Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Brown, JM; Hay, MP; Hogg, A; Pruijn, FB; Siim, BG; Sturman, JR; Wilson, WR, 2004
)
" Concerns that the adverse effects of chemotherapy are likely to outweigh its benefits have largely not been confirmed by quality-of-life data reported among patients with good performance status."( Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?
Albain, KS; Blackhall, FH; Shepherd, FA, 2005
)
" Tirapazamine (TPZ) is a bioreductive agent that forms a toxic free radical in hypoxia."( Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.
Reynolds, CP; Yang, B, 2005
)
"Hypoxia is an adverse prognostic feature of solid cancers that may be overcome with hypoxia-activated prodrugs (HAPs)."( Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
Abbattista, MR; Anderson, RF; Denny, WA; Guise, CP; Hay, MP; Hicks, KO; Lee, SJ; Li, D; Patterson, AV; Smaill, JB; Taghipouran, R; Tsai, A; Wilson, WR, 2020
)
" As expected, tirapazamine is progressively more toxic as oxygen levels decrease but retains some toxicity as oxygen is cycled between hypoxic and normoxic levels."( A multiwell plate-based system for toxicity screening under multiple static or cycling oxygen environments.
Gamcsik, MP; Walker, G; Yao, M, 2021
)

Pharmacokinetics

ExcerptReference
" These small species differences in protein binding are unlikely to have any major impact on the extrapolation of pharmacokinetic data from mice to humans."( Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation.
Graham, MA; Robin, H; Senan, S; Workman, P, 1995
)
" Pharmacokinetic studies for PGDE were conducted in mice at four dose levels ranging from one-tenth of the LD10 to the LD50."( Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
Eckhardt, N; Graham, MA; Greenslade, D; Hincks, J; Kaye, SB; Lendrem, D; Rampling, R; Robin, H; Senan, S; von Roemeling, R; Workman, P, 1997
)
" Pharmacokinetic studies revealed a greater than dose-proportional increase in the area under the plasma concentration x time curve (AUCs) of the two major metabolites."( Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.
Eckardt, N; Graham, MA; Kaye, SB; Lawson, N; McDonald, A; Rampling, R; Robin, H; Senan, S; von Roemeling, R; Wilson, P; Workman, P, 1997
)
" In this study, we develop a pharmacokinetic (PK)/pharmacodynamic (PD) model for TPZ that explicitly includes its diffusion characteristics as measured in multicellular layer (MCL) cultures of HT29 colon carcinoma cells."( Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures.
Denny, WA; Hicks, KO; Pruijn, FB; Sturman, JR; Wilson, WR, 2003
)
" It is suitable for the pharmacokinetic study of TPZ in rabbits."( [Study on HPLC determination method and pharmacokinetics of tirapazaming in rabbits].
Chen, H; Deng, Q; Zhang, D, 2006
)
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)

Compound-Compound Interactions

Human ovarian carcinoma cells of the line HO8910PM were cultured and treated with tirapazamine alone and with TPZ of different concentrations combined with LY294002 under aerobic and hypoxic conditions. The cytotoxic effects of singly or continuously administered tirapzamine (TPZ) and TX-402 were examined in combination with or without MTH in vivo.

ExcerptReference
"The influence of the hypoxic cell drug, SR-4233, alone and/or combined with ionizing radiations on the survival of two human cell lines having very different intrinsic radiosensitivity was analysed."( The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
Chavaudra, N; Guichard, M; Lambin, P; Malaise, EP, 1992
)
" In the present study, the in vivo effects of a promising hypoxic cytotoxin, tirapazamine (3-amino-1,2,4-benzotriazine 1,4-di-N-oxide), were examined in comparison with those of KU-2285, one of the best hypoxic cell radiosensitizers, in combination with both single and fractionated irradiation."( Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Abe, M; Hiraoka, M; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Takagi, T, 1996
)
"Recent data have shown that the in vitro and in vivo cytotoxicity of bioreductive drugs could be significantly increased when combined with chemotherapy drugs such as cisplatinum, depending on the timing of administration."( The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
Guichard, M; Lartigau, E, 1996
)
" AQ4N in combination with single dose radiation (12 Gy) and also with two fractionated radiation regimens was examined (5 x 3 Gy, one fraction per day; or 10 x 2 Gy fractions, 2 fractions per day with an 8 h interval)."( Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.
Friery, OP; Hejmadi, MV; Hirst, DG; McIntyre, IA; McKeown, SR; Patterson, LH, 1996
)
"A phase II study was undertaken to determine the efficacy of tirapazamine (TPZ) combined with cisplatin (cDDP) in patients with metastatic melanoma."( Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma.
Bedikian, AY; Buzaid, AC; Coates, S; Eton, O; Legha, SS; Neefe, J; Papadopoulos, N; Simmons, T; von Roemeling, R, 1997
)
"The TPZ-cDDP combination has definite activity against chemotherapy-naïve patients with cutaneous melanoma and warrant further studies in combination with other cytotoxic agents."( Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma.
Bedikian, AY; Buzaid, AC; Coates, S; Eton, O; Legha, SS; Neefe, J; Papadopoulos, N; Simmons, T; von Roemeling, R, 1997
)
" After injection of tirapazamine (TPZ), a bioreductive agent, combined with sodium borocaptate-10B (BSH) or dl-p-boronophenylalanine-10B (BPA) administration, the tumors were irradiated with thermal neutrons, and then isolated and incubated with cytochalasin-B (a cytokinesis blocker)."( Applicability of combination with tirapazamine in boron neutron capture therapy.
Akaboshi, M; Hori, H; Kinashi, Y; Kobayashi, T; Masunaga, S; Ono, K; Sakurai, Y; Suzuki, M; Takagaki, M, 1998
)
"A phase II study was undertaken to determine the efficacy of tirapazamine combined with cisplatin in patients with metastatic melanoma between April 1996 and April 1997."( Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma.
Bedikian, AY; Buzaid, AC; Eton, O; Legha, SS; McIntyre, S; Papadopoulos, N; Plager, C; Viallet, J, 1999
)
"Recent data have shown that the in vitro and in vivo cytotoxicity of bioreductive drugs could be significantly increased by combination with ionising radiation or chemotherapy."( [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
Guichard, M; Lartigau, E; Stern, S,
)
" Treatment of advanced and metastatic NSCLC with TPZ in combination with Gemcitabine/Cisplatin was well feasible and showed results recording to currently published data."( [Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)].
Gatzemeier, U; Groth, G; Nimmermann, C; Reck, M; von Pawel, J, 2004
)
"To evaluate the usefulness of continuous administration of hypoxic cytotoxins in terms of targeting acute hypoxia in solid tumours and the significance of combination with mild temperature hyperthermia (MTH) (40 degrees C, 60 min), the cytotoxic effects of singly or continuously administered tirapazamine (TPZ) and TX-402 were examined in combination with or without MTH in vivo."( The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Suzuki, M; Uto, Y, 2005
)
"We clarified the usefulness of the continuous administration of tirapazamine (TPZ) in combination with reduced dose-rate irradiation (RDRI) using gamma-rays or reactor thermal neutrons."( The usefulness of a continuous administration of tirapazamine combined with reduced dose-rate irradiation using {gamma}-rays or reactor thermal neutrons.
Hori, H; Kinashi, Y; Maruhashi, A; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Sakurai, Y; Suzuki, M; Uto, Y, 2006
)
"We clarified the usefulness of mild temperature hyperthermia (MTH) in combination with the continuous administration of tirapazamine (TPZ) under reduced dose-rate irradiation (RDRI) using gamma-rays."( The usefulness of mild temperature hyperthermia combined with continuous tirapazamine administration under reduced dose-rate irradiation with gamma-rays.
Hori, H; Kashino, G; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Suzuki, M; Uto, Y, 2007
)
" Further, MTH combined with TPZ raised the sensitivity of both the total and Q cell populations, especially the latter, under RDRI more markedly than under HDRI."( The usefulness of mild temperature hyperthermia combined with continuous tirapazamine administration under reduced dose-rate irradiation with gamma-rays.
Hori, H; Kashino, G; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Suzuki, M; Uto, Y, 2007
)
"From the viewpoint of solid tumour control as a whole, including intratumour Q-cell control, the use of TPZ, especially in combination with MTH, is useful for suppressing the reduction in the sensitivity of tumour cells caused by the decrease in irradiation dose rate in vivo."( The usefulness of mild temperature hyperthermia combined with continuous tirapazamine administration under reduced dose-rate irradiation with gamma-rays.
Hori, H; Kashino, G; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Suzuki, M; Uto, Y, 2007
)
"To study the inhibitory effect of tirapazamine (TPZ) combined with LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), on the growth of human ovarian carcinoma cells."( [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
Ren, Y; Zha, X; Zhang, GN, 2007
)
"Human ovarian carcinoma cells of the line HO8910PM were cultured and treated with tirapazamine alone and treated with TPZ of different concentrations combined with LY294002 of the concentration of 50 micromol/L respectively under aerobic and hypoxic conditions."( [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
Ren, Y; Zha, X; Zhang, GN, 2007
)
" The IC(50) value of TPZ combined with LY294002 on the HP8910PM cells under hypoxic condition was 22."( [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
Ren, Y; Zha, X; Zhang, GN, 2007
)
" LY294002 increases the inhibitory effect of TPZ on the ovarian cancer cells, compared with TPZ treatment alone, TPZ combined with LY294002 decreases the IC(50) of HO8910PM and OVCAR-3 cells significantly."( [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
Ren, Y; Zha, X; Zhang, GN, 2007
)
" Here, we demonstrate that PTT combined with chemotherapy can efficiently elicit immunity to suppress metastatic tumor growth."( Immune remodeling triggered by photothermal therapy with semiconducting polymer nanoparticles in combination with chemotherapy to inhibit metastatic cancers.
Hu, Q; Huang, W; Li, L; Liu, J; Wang, Z; Xu, M; Yang, Y, 2021
)
" This study aimed to explore the effects of ABZSO nanoparticles (ABZSO NPs), TPZ combined with PDT on the activity of Egs in vitro and in vivo."( Tirapazamine combined with photodynamic therapy improves the efficacy of ABZSO nanoparticles on Echinococcosis granulosus via further enhancing "breaking-then-curing".
Aimaiti, W; Gong, Y; Huang, Z; Jiang, H; Lin, Y; Wang, J; Wen, H; Xu, Y; Yang, J; Zhou, T, 2023
)
"ABZSO NPs combined with TPZ and PDT has a better inhibitory effect on the growth of Egs in vitro and in vivo based on the strategy of "breaking-then-curing"."( Tirapazamine combined with photodynamic therapy improves the efficacy of ABZSO nanoparticles on Echinococcosis granulosus via further enhancing "breaking-then-curing".
Aimaiti, W; Gong, Y; Huang, Z; Jiang, H; Lin, Y; Wang, J; Wen, H; Xu, Y; Yang, J; Zhou, T, 2023
)

Bioavailability

ExcerptReference
" Oral dosing gave lower peak plasma drug concentrations (2-3 micrograms ml-1) but reasonable bioavailability (75%)."( Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton, MI; Workman, P, 1993
)
" However, unsatisfactory clinical outcomes resulting from the low bioavailability of the low-molecular TPZ and TPZD limited their further applications."( Zwitterionic Block Copolymer Prodrug Micelles for pH Responsive Drug Delivery and Hypoxia-Specific Chemotherapy.
Diaz-Dussan, D; Duan, W; Hao, X; Kong, L; Narain, R; Peng, YY; White, J; Zhao, J, 2022
)

Dosage Studied

ExcerptReference
" In rats dosed with SR 4233 in vivo, significantly higher levels of 8-hydroxydeoxyguanosine could be detected in liver, compared to vehicle-dosed controls."( Genotoxic effects of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and nitrogen mustard-N-oxide (nitromin) in Walker carcinoma cells under aerobic and hypoxic conditions.
Cahill, A; Jenkins, TC; Pickering, P; White, IN, 1995
)
" This was observed after both a systemic dose of SR 4233 and direct dosing to the tissue through the microdialysis probe."( Microdialysis sampling in tumor and muscle: study of the disposition of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (SR 4233).
Lunte, CE; Palsmeier, RK, 1994
)
" Oral dosing gave lower peak plasma drug concentrations (2-3 micrograms ml-1) but reasonable bioavailability (75%)."( Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton, MI; Workman, P, 1993
)
" The radiation dose-response curves of MN frequency suggested that the interaction of tirapazamine with irradiation appeared to be essentially additive in both cell lines."( Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Abe, M; Hiraoka, M; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Takagi, T; Takahashi, M, 1996
)
" Grouped data indicate that visual acuity was not affected by either dosage of chemotherapy."( Evaluation of ocular safety: tirapazamine plus cisplatin in patients with metastatic melanomas.
Bedikian, AY; Kellaway, J; McIntyre, S; Prager, TC; Urso, RG; Zou, Y, 1998
)
" Platinum schedules other than bolus dosing every 3 to 4 weeks are effective and may be less toxic."( Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum.
Brizel, DM; Esclamado, R, 2006
)
"Radiation dosage constraints and hypoxia-associated resistance lead to the failure of radiotherapy (RT), especially in hypoxic liver cancer."( Janus Gold Triangle-Mesoporous Silica Nanoplatforms for Hypoxia-Activated Radio-Chemo-Photothermal Therapy of Liver Cancer.
Chang, ZM; Chen, F; Dong, WF; Ge, MF; Hu, R; Li, L; Shao, D; Wang, Y; Wang, Z; Zhang, F; Zheng, X, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
N-oxide
benzotriazinesCompounds based on a fused triazine and benzene ring skeleton.
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki50.00000.00021.10439.9000AID1425990
Carbonic anhydrase 1Homo sapiens (human)Ki50.00000.00001.372610.0000AID1425987
Carbonic anhydrase 2Homo sapiens (human)Ki50.00000.00000.72369.9200AID1425988
Carbonic anhydrase 9Homo sapiens (human)Ki50.00000.00010.78749.9000AID1425989
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (141)

Assay IDTitleYearJournalArticle
AID329297Cytotoxicity against human H460 cells under hypoxic condition after 2 hrs by Alamar blue staining assay2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.
AID268854Ratio of cytotoxicity against human Molt4 cells in normoxia to hypoxia after 48 hrs2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID587585Cytotoxicity against human A549 cells for 72 hrs under hypoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID224106Concentration required to reduce plating efficiency to 10 percent of controls, under aerobic conditions in mouse SCCVII tumor cells.2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID229941Hypoxic cytotoxicity ratio was measured as C10 aerobic/C10 hypoxic2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
AID268847Cytotoxicity against human Molt4 cells after 48 hrs by MTT assay2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID268851Cytotoxicity against human PC3 cells after 48 hrs by MTT assay2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID1651884Ratio of GI50 for human A549 cells in oxic condition to GI50 for anoxic condition2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
AID124099in vivo activity against aerobic and hypoxic cells in RIF-1 tumors when administered at a dose of 225 umol/kg in mice after 5 min of exposure to radiation2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
AID409717Cytotoxicity against mouse EMT6/KU cells in hypoxic condition for 5 hrs measured after 7 to 10 days2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
AID389729Drug diffusion coefficient in human HT-29 multicellular layer under 95% oxygen by liquid scintillation counting2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID229942Hypoxic cytotoxicity ratio was measured as IC50 aerobic/IC50 hypoxic2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
AID268853Cytotoxicity against human Molt4 cells in hypoxia after 48 hrs2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID304260Cytotoxicity against human SiHa cells under hypoxic conditions after 4 hrs2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID1174873Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
AID389727Cytotoxicity against human SiHa cells after 4 hrs under strict hypoxic condition2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID225044Inhibitory concentration against murine SCCVII cell line under hypoxic condition2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID304265Cmax in CD1 mouse at 133 umol/kg, ip2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID115134In vivo toxicity against C3H/HeN cell line in mice expressed as maximal tolerated dose2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
AID225046Interexperimental ratio of hypoxic TPZ C10 to hypoxic BTO C10 using murine SCCVII cell line2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID587579Cytotoxicity against human SMMC7721 cells for 72 hrs under hypoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID389728Hypoxic cytotoxicity ratio, ratio of aerobic IC50 to anoxic IC50 for human SiHa cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID389725Cytotoxicity against human HT-29 cells after 4 hrs under strict hypoxic condition2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1315317Cytotoxicity against human HCT116 cells measured after 48 hrs under hypoxic condition by CCK8 assay2016Journal of natural products, 05-27, Volume: 79, Issue:5
Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction.
AID689773Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID226468Intraexperimental difference between the hypoxic and aerobic cytotoxicity in mouse SCCVII tumor cells2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID409716Cytotoxicity against mouse EMT6/KU cells in aerobic condition for 5 hrs measured after 7 to 10 days2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
AID221988Inhibitory concentration against human adenocarcinoma HT-29 cell line under aerobic condition2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID1425993Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1726726Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID249256Partition coefficient (logP) of the compound2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.
AID1594185Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID389733Drug metabolism in human HT-29 cells assessed as amount of drug metabolized for one log of cell kill at their CT10 concentration for 1 hr2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID389730Metabolic stability in human HT-29 multicellular layer assessed as apparent first-order rate constant under anoxic condition2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID304286Antitumor activity against human HT29 cells implanted in CD1 mouse assessed as clonogenic survival at 133 umol/kg, ip after 18 hrs relative to control2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID224107Concentration required to reduce plating efficiency to 10 percent of controls, under hypoxic conditions in mouse SCCVII tumor cells.2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID83580Concentration required to kill aerobic HT-29 human colon carcinoma cells in vitro2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
AID1364439Antiproliferative activity against human MOLM13 cells after 24 hrs under 2% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives.
AID587580Cytotoxicity against human SMMC7721 cells for 72 hrs under normoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID268856Cytotoxicity against human HL60 cells in hypoxia after 48 hrs2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID1425987Binding affinity to recombinant human carbonic anhydrase 1 after 15 mins by stopped-flow CO2 hydration assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID226463Hypoxia cytotoxicity ratio (HCR), calculated by dividing the dose in air by the dose in hypoxia giving 1% control cell survival.1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2.
AID1175521Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID1594193Selectivity ratio of IC50 for human SW620 cells under aerobic condition to IC50 for human SW620 cells under hypoxic condition2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID1425990Binding affinity to recombinant human carbonic anhydrase 12 after 15 mins by stopped-flow CO2 hydration assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID224109Intraexperimental ratio of hypoxic TPZ C10 to hypoxic BTO C10 in mouse SCCVII tumor cells.2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID481203Hypoxic cytotoxicity ratio, concentration required to kill 99% chinese hamster V79 cells under aerobic condition to hypoxic condition2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.
AID1315316Cytotoxicity against human HCT116 cells measured after 18 hrs under hypoxic condition by CCK8 assay2016Journal of natural products, 05-27, Volume: 79, Issue:5
Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction.
AID304264Toxicity in ip dosed CD1 mouse2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID1175524Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID304259Ratio of IC50 for HT29 cells under oxic conditions to hypoxic conditions after 4 hrs2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID124097in vivo activity against aerobic and hypoxic cells in RIF-1 tumors when administered at a dose of 225 umol/kg in mice2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
AID481201Cytotoxicity against chinese hamster V79 cells under aerobic condition at 30 uM after 7 days by crystal violet staining2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.
AID268855Cytotoxicity against human HL60 cells in normoxia after 48 hrs2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID268857Ratio of cytotoxicity against human HL60 cells in normoxia to hypoxia after 48 hrs2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID489582Growth inhibition of human U251 cells after 48 hrs by SRB assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents.
AID304297Protein binding in mouse plasma by equilibrium dialysis2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID389726Hypoxic cytotoxicity ratio, ratio of aerobic IC50 to anoxic IC50 for human HT-29 cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID213608Concentration giving 1% of control V79 cells survival in hypoxia1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2.
AID587586Cytotoxicity against human A549 cells for 72 hrs under normoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID1651883Cytotoxicity against human A549 cells incubated for 4 hrs in anoxic condition followed by oxic exposure for 48 hrs by sulforhodamine B assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
AID409718Hypoxic cytotoxicity ratio of IC50 for mouse EMT6/KU cells in aerobic condition to IC50 for mouse EMT6/KU cells in hypoxic condition2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
AID304279AUC in CD1 mouse at 133 umol/kg, ip2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID200611Concentration required to kill aerobic mouse SCCVII cells in vitro2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
AID1425996Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1364437Antiproliferative activity against human MOLM13 cells after 24 hrs under 19% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives.
AID689771Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate ITR after 7 days by luminescence spectrometry2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1175520Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID304296Drug penetration in anoxic human HT29 cells assessed as penetration half distance2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID1594190Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID587587Cytotoxicity against human PC3 cells for 72 hrs under hypoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID304263Effect on human HT29 cells under hypoxic conditions assessed as drug level causing 10% clonogenic survival2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID304261Ratio of IC50 for SiHa cells under oxic conditions to hypoxic conditions after 4 hrs2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID1315314Cytotoxicity against human LNCAP cells measured after 18 hrs under hypoxic condition by CCK8 assay2016Journal of natural products, 05-27, Volume: 79, Issue:5
Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction.
AID689772Antitubercular activity against Mycobacterium tuberculosis H37Rv incubated for 10 days in anaerobic condition followed by 48 hrs incubation in aerobic condition by LORA assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID268858Induction of apoptosis in human Molt4 cells after 24 hrs at 2 uM2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1651882Cytotoxicity against human A549 cells incubated for 52 hrs in oxic condition by sulforhodamine B assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
AID124098in vivo activity against aerobic and hypoxic cells in RIF-1 tumors when administered at a dose of 225 umol/kg in mice 30 min before exposure to radiation2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
AID304272Half life in CD1 mouse at 133 umol/kg, ip2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID1315318Cytotoxicity against human COLO205 cells measured after 48 hrs under hypoxic condition by CCK8 assay2016Journal of natural products, 05-27, Volume: 79, Issue:5
Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction.
AID587588Cytotoxicity against human PC3 cells for 72 hrs under normoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID689770Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate SRI after 5 days by resazurin-based microplate assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID304291Antitumor activity against human HT29 cells implanted in CD1 mouse at 133 umol/kg, ip administered 5 mins after irradiation by excision assay relative to radiation alone2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID389732Cytotoxicity against human HT-29 cells assessed as AUC-time curve providing 10% surviving fraction by clonogenic assay2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID587583Cytotoxicity against human KB cells for 72 hrs under hypoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID221987Inhibitory concentration against human adenocarcinoma HT-29 cell line under hypoxic condition2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID225045Inhibitory concentration against murine SCCVII cell line under aerobic condition2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID1425994Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID1175523Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID28960Partition coefficient (logP)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID329298Cytotoxicity against human H460 cells under normoxic condition after 2 hrs by Alamar blue staining assay2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.
AID226466Interexperimental difference between the hypoxic and aerobic cytotoxicity using murine SCCVII cell line2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID1726727Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID389731Extravascular transport in human HT-29 multicellular layer assessed as half penetration distance under anoxic condition2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID1425988Binding affinity to recombinant human carbonic anhydrase 2 after 15 mins by stopped-flow CO2 hydration assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID115129In vivo maximum tolerated dose giving 20% weight loss within 3 days of a single ip administration.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
AID268852Cytotoxicity against human Molt4 cells in normoxia after 48 hrs2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID587582Cytotoxicity against human K562 cells for 72 hrs under normoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID389724Solubility at 22 degC in culture medium in presence of 5% fetal calf serum2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
AID1594188Selectivity ratio of IC50 for human MDA-MB-468 cells under aerobic condition to IC50 for human MDA-MB-468 cells under hypoxic condition2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID226465Interexperimental difference between the hypoxic and aerobic cytotoxicity using human adenocarcinoma HT-29 cell line2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID1594184Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID489581Growth inhibition of human HepG2 cells after 48 hrs by SRB assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents.
AID1425989Binding affinity to recombinant human carbonic anhydrase 9 after 15 mins by stopped-flow CO2 hydration assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID268848Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID233367Hypoxia cytotoxicity ratio (dose in air / hypoxia giving 99% of cell killing)1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
AID304262Diffusion coefficient, D in HT29 multicellular layers2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID268850Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID304257Solubility in culture medium in presence of 5% fetal calf serum2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID587581Cytotoxicity against human K562 cells for 72 hrs under hypoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID1594189Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID268849Cytotoxicity against human K562 cells after 48 hrs by MTT assay2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID1726728Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID1175522Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
AID1174872Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
AID83581Concentration required to kill hypoxic HT-29 human colon carcinoma cells in vitro2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
AID213609The compound was tested for potency by measuring the concentration (umolar) that gives 1% clonogenic cell survival in hypoxia1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID689774Selectivity index, ratio of CC50 for Vero cells to MIC90 for Mycobacterium tuberculosis H37Rv isolate SRI2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
AID268860Increase in p53 level in human Molt4 cells in hypoxia after 24 hrs at 2 uM2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID304258Cytotoxicity against human HT29 cells under hypoxic conditions after 4 hrs2007Journal of medicinal chemistry, Dec-13, Volume: 50, Issue:25
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
AID329299Ratio of IC50 for human H460 cells under normoxic condition to hypoxic condition by Alamar blue staining assay2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.
AID1726729Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID268859Reduction of mitochondrial membrane potential in human Molt4 cells after 12 hrs at 2 uM2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID1425995Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.
AID409715Inhibition of indoleamine 2,3-dioxygenase in aerobic condition2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
AID1726730Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID221989Interexperimental ratio of hypoxic TPZ C10 to hypoxic BTO C10 using human adenocarcinoma HT-29 cell line2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
AID481202Cytotoxicity against chinese hamster V79 cells under anaerobic condition at 2.0 uM after 7 days by crystal violet staining2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.
AID587584Cytotoxicity against human KB cells for 72 hrs under normoxic condition by MTT assay2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
AID200612Concentration required to kill hypoxic mouse SCCVII cells in vitro2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (467)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (3.00)18.7374
1990's156 (33.40)18.2507
2000's148 (31.69)29.6817
2010's91 (19.49)24.3611
2020's58 (12.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials44 (9.09%)5.53%
Reviews42 (8.68%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other398 (82.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer[NCT02174549]Phase 1/Phase 225 participants (Anticipated)Interventional2014-09-30Active, not recruiting
Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer[NCT00006484]Phase 30 participants Interventional2000-11-30Completed
A Phase I Study Of Tirapazamine/Cisplatin/Etoposide And Concurrent Thoracic Radiotherapy For Limited Stage Small Cell Lung Cancer[NCT00006487]Phase 130 participants (Actual)Interventional2000-10-31Completed
A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis[NCT00262821]Phase 3402 participants (Actual)Interventional2006-02-28Terminated(stopped due to Study drug no longer available resulting in lack of study drug for participants.)
A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer[NCT00066742]Phase 272 participants (Actual)Interventional2003-09-30Completed
Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer[NCT00174837]Phase 3317 participants (Actual)Interventional2005-04-30Completed
An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab[NCT04701476]Phase 2110 participants (Anticipated)Interventional2021-05-20Recruiting
Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody[NCT03259867]Phase 254 participants (Anticipated)Interventional2017-07-01Recruiting
Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer[NCT00094081]Phase 3861 participants (Actual)Interventional2002-10-31Completed
A Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors[NCT00003288]Phase 112 participants (Actual)Interventional1998-08-31Completed
A Phase I Study Of Tirapazamine In Combination With Radiation And Weekly Cisplatin In Patients With Locally Advanced Cervical Cancer[NCT00098995]Phase 122 participants (Anticipated)Interventional2004-12-31Completed
Phase I Dose Escalation Study of Tirapazamine (NSC 130181) in Combination With Carboplatin and Paclitaxel in Advanced Malignant Solid Tumors[NCT00005078]Phase 144 participants (Actual)Interventional2000-03-31Completed
A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination With Vincristine And Pilot Assessment of Safety and Efficacy of Tirapazamine Combined With Multiagent Chemotherapy for First Relapse or Progressive Diseas[NCT00025363]Phase 2150 participants (Actual)Interventional2001-11-30Completed
The International Tirazone Triple Trial (i3T): A Phase III, Randomized Efficacy And Safety Study Of The Combination Chemotherapy With Tirapazamine+Cisplatin+Vinorelbine Versus Cisplatin+Vinorelbine In Subjects With Inoperable, Previously Untreated, Non-Sm[NCT00017459]Phase 30 participants Interventional2000-07-31Completed
A Phase II Evaluation of Tirapazamine (NSC #130181, IND #46,525) in Combination With Cisplatin in Recurrent Platinum Sensitive Ovarian or Primary Peritoneal Cancer[NCT00020696]Phase 20 participants Interventional2001-06-30Completed
A Phase I Study Of Tirapazamine (NSC 130181) Paclitaxel And Carboplatin With Concurrent Radiation Followed By Tirapazamine/Paclitaxel/Carboplatin Consolidation For Stage III Non-Small Cell Lung Cancer[NCT00033410]Phase 130 participants (Anticipated)Interventional2002-03-31Completed
Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer[NCT00002774]Phase 263 participants (Actual)Interventional1996-06-30Completed
Evaluation of Intravenously Administered Tirapazamine Plus Cisplatin in Cervical Cancer[NCT00003369]Phase 256 participants (Actual)Interventional1998-08-31Completed
TATE Versus TACE, an Open-label Randomized Study Comparing TransArterial Tirapazamine Embolization Versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma[NCT03145558]Phase 2134 participants (Anticipated)Interventional2017-12-05Suspended(stopped due to on hold by sponsor)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00066742 (3) [back to overview]Overall Survival
NCT00066742 (3) [back to overview]Progression-Free Survival
NCT00066742 (3) [back to overview]Response Rate (Confirmed and Unconfirmed Complete and Partial Responses Per RECIST) in the Subset of Patients With Measurable Disease at Baseline.
NCT00262821 (3) [back to overview]Overall Survival
NCT00262821 (3) [back to overview]Progression-free Survival - Percentage of Patients Alive and Progression Free
NCT00262821 (3) [back to overview]Adverse Events (Grade 3 or Higher) During Treatment Period

Overall Survival

Overall survival was defined as the time from date of enrollment until the date of death due to any cause. Patients last known to be alive were censored at the date of last conatct. Patients were followed for a maximum of 3 years from the date of enrollment. (NCT00066742)
Timeframe: Weekly during protocol treatment, then every 3 months for first year, then every 6 months for up to 3 years after enrollment.

Interventionmonths (Median)
Evaluable Patients21

[back to top]

Progression-Free Survival

Progression was defined as a >= 20% increase in the sum of longest diameters of measurable lesions over the smallest sum observed or unequivocal progression of non-measurable disease or the appearance of any new lesion/site. Symptomatic deterioration was defined as a global deterioration of health status requiring discontinuation of treatment. Progression-free survival was defined as the time from the date of enrollment until the date of progression, symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at last contact date. (NCT00066742)
Timeframe: At end of concurrent chemoradiotherapy (Week 8), then at end of consolidation chemotherapy (Week 15). After off treatment, every 3 months for the first 2 years then every 6 months for up to 3 years after enrollment.

Interventionmonths (Median)
Evaluable Patients11

[back to top]

Response Rate (Confirmed and Unconfirmed Complete and Partial Responses Per RECIST) in the Subset of Patients With Measurable Disease at Baseline.

A complete response (CR) was defined as a complete disappearance of all disease with no new lesions. A partial response (PR) was defined as at least a 30% decrease under baseline of the sum of longest diameters of all target measurable lesions with no unequivocal progression of non-measurable disease and no new lesions. Both CR and PR had to be confirmed by a second determination at least 4 weeks apart. All disease had to be assessed using same method as baseline. Only patients with measurable disease at baseline were included in this analysis. (NCT00066742)
Timeframe: After completeion of concurrent chemotherapy+radiation (Week 8); then after completion of consolidation chemotherapy (Week15); once off treatment, every 3 months until disease progression for a maximum of 3 years after enrollment.

Interventionparticipants (Number)
Complete ResponseUnconfirmed Complete ResponsePartial ResponseUnconfirmed Partial ResponseNo response
Evaluable Patients With Measurable Disease0723024

[back to top]

Overall Survival

The observed length of life from entry into the study to death or date of last contact. (NCT00262821)
Timeframe: From study entry to death or last contact, up to 6 years

Interventionpercentage of patients alive (Number)
Concurrent Cisplatin and Radiation70.6
Concurrent Cisplatin, Tirapazamine and Radiation70.5

[back to top]

Progression-free Survival - Percentage of Patients Alive and Progression Free

Patients' progression status based on clinical, radiological or pathological (histological) evidence of disease after study therapy. Progression includes any death without evidence of disease progression. Progression-free Survival (PFS) is defined as time in month from study enrollment to disease progression, death or date of last contact. (NCT00262821)
Timeframe: From study entry until first disease progression, death or date of last contact, up to 6 years

Interventionpercentage of patients (Number)
Concurrent Cisplatin and Radiation64.4
Concurrent Cisplatin, Tirapazamine and Radiation63.0

[back to top]

Adverse Events (Grade 3 or Higher) During Treatment Period

Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v3.0. (NCT00262821)
Timeframe: All Adverse Events (AEs) occuring during treatment and up to 30 days after stopping the study treatment are reported

,
Interventionparticipants (Number)
Number Participants AnalyzedLeukopeniaThrombocytopeniaNeutropeniaAnemiaOther hematologicAllergy/ImmunologyCardiacCoagulationConstitutionalDermatologicGastrointestinalGenitourinary/RenalHemorrhageInfectionMetabolicMusculoskeletalNeuropathyOther NeurologicalPainPulmonaryVascular DisordersDeath, Not CTC Coded
Concurrent Cisplatin and Radiation19051830162003015028451428015103114
Concurrent Cisplatin, Tirapazamine and Radiation180536261217241231735451445511438670

[back to top]